SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against CytRx Corp. & Encourages Investors with...

Goldberg Law PC (the “Firm”) announces that a class action lawsuit has been filed against CytRx Corporation (“CytRx” or the “Company”) (Nasdaq: CYTR). Investors who purchased or otherwise acquired shares between November 18, 2014 and June 11, 2016 (the “Class Period”) are encouraged to contact the Firm in advance of the September 23, 2016 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at [e-mail].

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the complaint, CytRx made materially false and misleading statements and/or failed to disclose material facts, specifically: that the clinical hold placed on the Phase 3 trial of aldoxorubicin for soft tissue sarcomas would prevent enough follow-up for patients involved in the study; that nearly half of all patients would be excluded from the data since the study was disturbed by a partial clinical hold; that the Company would likely conduct a second analysis as a result; and that the results of the trial could be materially affected and/or approval of aldoxorubicin for soft tissue sarcomas could be delayed. On July 11, 2016 the Company issued a press release revealing that the Phase 3 clinical trial of aldoxorubicin did not show any improvement from other commonly used cancer drugs and that nearly half of the patients in the Phase 3 trial were excluded from the data since the study was disturbed by a partial clinical hold on November 2014. When this news was disclosed, shares of CytRx dropped in value sharply, causing investors harm.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160812005497/en/

Goldberg Law PC, Los AngelesMichael Goldberg, Esq., 800-977-7401Brian Schall, Esq., [e-mail]